Scinai Immunotherapeutics Ltd (SCNI)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility PR Newswire JERUSALEM...

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form F-3 - Registration statement by foreign private issuers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]